Barclays PLC Graphite Bio, Inc. Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$2.24 - $2.66 $108,447 - $128,781	48,414 Added 142.24%	82,451 $216,000
Q3 2023 Nov 07, 2023	BUY	$2.18 - $2.77 $61,916 - $78,673	28,402 Added 504.03%	34,037 $85,000
Q2 2023 Aug 03, 2023	SELL	$2.47 - $3.38 $43,657 - $59,741	-17,675 Reduced 75.83%	5,635 $15,000
Q1 2023 May 04, 2023	BUY	$1.85 - $3.21 $43,123 - $74,825	23,310 New	23,310 $57,000
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $18,787 - $45,914	-8,779 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.1 - $13.06 $44,772 - $114,653	8,779 New	8,779 $44,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.